Cannabis Europa is excited to announce Grow Biotech as our Silver Sponsor for the Cannabis Europa: Transatlantic Forum at the Fairmont Royal York Hotel in Toronto on November 5th.

Grow Biotech is a British company that develops revolutionary processes, practices, techniques, tools and formulations in order to unlock the medical potential of cannabis for those who need it. Grow Biotech’s market access team is involved in launching medical cannabis producers’ businesses into new markets and their R&D team creates new technologies that support the producers so they create better, more cost-effective and readily available medicines.

Grow Biotech will be joining the Cannabis Europa: Transatlantic Forum in Toronto to share their expertise on how to navigate through the complex European regulatory framework that surrounds the medicinal cannabis industry.

Grow Biotech are industry leaders. Their passion for innovation where it is most needed gives us faith in the future of this vital and disruptive industry. – George McBride, Founder and CEO of Hanway Associates and Co-Founder of Cannabis Europa

In February 2019, the first bulk shipment of cannabis-based medicine was successfully imported into the UK, this historical moment for the medical cannabis industry was made possible by Grow Biotech. Since then, Grow Biotech has partnered with IPS Pharma, a pharmaceutical importer, distributor and manufacturer with over 18 years of experience in the unlicensed and licensed medicine industry. Together, Grow Biotech and IPS Pharma have created Logist Pharma, which has been responsible for a further seven bulk imports of medical cannabis into the UK. This joint venture combines Grow Biotech’s unparalleled medical cannabis expertise with IPS Pharma’s market-leading capabilities in order to facilitate the import of cannabis products worldwide with the intent of maximising patient access and aid the research and development of cannabis-based medicines.

While regulations may have changed, patients continue to struggle to access the cannabis medicines they need. The joint venture we have agreed with IPS is focused first and foremost on positive patient outcomes. We feel we are perfectly placed to facilitate the growth in the UK medical cannabis industry with our deep cannabis knowledge and our track-record of raising and deploying capital. Ben Langley, CEO of Grow Biotech

The first of November marked one full year since the UK legalised the use of medical cannabis. Within this year, Grow Biotech and Logist have ensured a steady supply of medical cannabis lowering the monthly prescription cost of this medicine by 27%, something that was made possible by importing larger quantities. Grow Biotech is confident that UK regulations can be successfully navigated, making this medicinal plant more readily available to researchers and patients, as well as through the National Health Service (NHS). Going forward, the company’s aim is to expand to the rest of the European market, with a number of expansion options already in progress.

Over the next twelve months, we expect the UK’s medical community as a whole to take on the challenge of understanding how cannabis might help their patients. We are expecting leading consultants to publish papers on the impact they have seen on their patients, as well as evidence gathered through MHRA-approved trials. This will significantly improve the data available to regulators, policymakers and NICE. – Hari Guliani, COO of Grow Biotech

Join us on November 5th at the Fairmont Royal York Hotel in Toronto to learn about the latest news concerning research, innovation and the production of medicinal cannabis in Europe from those who are at the forefront of this change.

Related posts